(January 29, 2018) A study recently published in the New England Journal of Medicine looked at the difference between two treatment strategies for newly diagnosed stage III epithelial ovarian cancer patients, with the goal of identifying the treatment with a higher rate of recurrence free survival. The first treatment option, typical for advanced stage ovarian … Continued
(January 25, 2018) CancerSEEK is a blood test designed to detect cancer by analyzing levels of proteins and mutations in cell-free DNA. The goal of this particular blood test is to assist in early detection, and therefore decrease cancer related deaths, for ovarian, liver, stomach, pancreas, esophagus, colorectum, lung, and/or breast cancers. The results of … Continued
(January 25, 2018) OCRFA has just awarded more than $5.3 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $80 million. This year’s grants have been awarded to twenty top scientists at sixteen leading medical centers across the country. “Our 2018 grantees are truly some of … Continued
Make your 2017 tax-deductible gift NOW! We work every day to fund cures, foster community, further conversations and ultimately, advance the cause. We do this by supporting women fighting ovarian cancer and the friends and families who love them, by working with scientists to eradicate the disease and policymakers who make it possible, and by … Continued
(December 28, 2017) Progress is being made every day, and scientists are on the threshold of many more important discoveries – but we need your help to continue investing in cutting-edge research that will one day lead to a cure, and to keep fighting on Capitol Hill for policies that help women receive the highest … Continued
(December 20, 2017) Cell Reports published new research from the Wistar Institute, which looked at the potential benefits of a therapy that combines PARP inhibitors and BET inhibitors for ovarian cancer patients without BRCA mutations. The research was funded in part by an OCRFA grant to Rugang, Zhang, PhD. PARP inhibitors have already been approved … Continued
(December 14, 2017) For over two decades, you have made it possible for OCRFA to fund the most innovative and promising science, resulting in research breakthroughs that have advanced our understanding of ovarian cancer, how it starts and new treatment options, and you have enabled OCRFA to successfully advocate for federal research dollars and provide … Continued
(December 11, 2017) A study by the Ovarian Tumor Tissue Analysis Consortium, published in JAMA Oncology, looked at the association between cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) and overall survival with certain types of ovarian cancer. After an immunohistochemical analysis of 5,577 patients, researchers saw a strong correlation between high levels of CD8+ TILs and longer … Continued
(December 8, 2017) The results of the CONCORD-2 study, recently published in Cancer, show a large difference in ovarian cancer survival between black women and white women, and also between stages at diagnosis. The data collected from the study, the largest of its kind, looked at 172,849 cases of ovarian cancer, over the course of … Continued
(December 4, 2017) The results of a phase II trial, which focused on stages IIB to IVA epithelial ovarian cancer, were recently published in the Annals of Oncology. The primary purpose of the six year, two stage, multicenter trial was to look at the nine month progressive disease rate when using intraperitoneal (IP) chemotherapy after … Continued
Turn Up the Heat is a foodie’s paradise, featuring treats and libations from more than 50 incredible local women chefs, mixologists, and restaurateurs. Join us on Wednesday, March 7th at the Ronald Reagan Building and International Trade Center in Washington, DC to support Ovarian Cancer Research Alliance. Until December 1st, when you buy a General … Continued
(November 22, 2017) A recent paper published in the Journal of Clinical Investigation reports that a subset of ovarian cancers reduce the expression of a critical gene involved in recycling the cells’ proteins, known as ubiquitin B (UBB). Silencing the expression of a closely related gene, also in the ubiquitin family, that performs an identical … Continued
Get email updates about research news, action alerts, and ways to join the fight.
